The GGOMed
Private Urology Thesis
Prepared for Chelsea and Westminster Hospital | Jan 2026
Doc: GGO-X-2026-V2
01. Executive Summary
GGOMed proposes a tiered transformation of Chelsea & Westminster's private urology offering, transitioning from reactive billing to fixed-price clinical pathways.
By leveraging existing infrastructure with zero initial capital expenditure in Tier 1, we can capture high-volume day-case surgery and diagnostics that currently leak to competitors (HCA, Cleveland Clinic). Tier 2 and Tier 3 provide a clear reinvestment roadmap to unlock specialized diagnostic capabilities and robotic-assisted MIST surgery.
"The Structural Arbitrage Opportunity"
C&W possesses sunk-cost infrastructure that for-profit competitors must amortize. By utilizing marginal capacity, we can deliver superior margins while undercutting competitor pricing by up to 55%.
Year 1 Revenue Target
£1.40M
Based on conservative benchmarks
Tier 1 Gross Profit
£318K
Zero Capital Expenditure required
Portfolio ROI
404%
Aggregated across Tier 1 & 2
02. Tier 1: Foundation (The Soft Launch)
Zero Capital,
Maximum Velocity
Phase 1 utilizes current theatres, outpatient rooms, and existing imaging capacity. We launch with 6 "Ready Bundles" where the trust already possesses a distinctive clinical advantage.
- Adult Circumcision (56% price advantage)
- Haematuria One-Stop (Integrated CT/Cysto)
- ED Diagnostic Suite (Ollandini Protocol)
- Microsurgical Fertility (Integrated ACU)
Tier 1 Unit Economics
03. Tier 2: Enhanced Launch
Investment 2A: LUTS Diagnostics
Unlocks high-frequency prostate screening and bladder assessment. Requires capital for Uroflowmetry and PVR scanning.
Investment 2B: Li-ESWT Machine
Introduces regenerative shockwave therapy for ED. High-margin derivative revenue from initial diagnostic suite.
Financial Projection: Tier 1 + 2
Total Investment
£112,500
Annual Revenue
£1,399,500
Annual GP
£454,650
Aggregate ROI
404%
04. Tier 3: Future Expansion (MIST Surgery)
Do NOT Invest in Year 1
Wait until Month 12 to evaluate LUTS diagnostic volume. Tier 3 investment (£70K - £600K) unlocks surgical conversion for LUTS patients, capturing up to £150K+ per year in additional revenue.
Wait & Verify: Evaluate average prostate sizes and patient willingness after 80+ assessments.
Technology Choice: Decide between Rezūm (£70K), GreenLight (£245K), or Aquablation (£610K).
05. Implementation Roadmap
Phase 1 (Weeks 1-4)
Governance & Approval
- Medical Director/COO/CFO sign-off
- Radiology SLA negotiation (CT slots)
- Marketing (£15K) and IT (£8K) budget allocation
Phase 2 (Weeks 3-6)
Service Network Build
- Recruit 2-3 additional consultants to Ollandini Panel
-
Standardize professional fee agreements
Phase 4-5 (Weeks 8-12)
Soft Launch (Tier 1)
Digital pre-payment portal live. Google Ads launch (£15K budget). Service launch for ED, Haematuria, Circumcision, and Microsurgery.
Phase 6 (Months 4-6)
Tier 2 Capital Commissioning
Uroflowmetry, PVR scan, and Li-ESWT machines installed and staff trained. Launch LUTS diagnostic bundle.
Month 12 Decision Point
Tier 3 (MIST) Investment Review
Full audit of LUTS volumes. Decision on Rezūm/GreenLight acquisition for Year 2 surgical capture.
06. Verification & Governance
Objection Handling
"Radiology doesn't have CT slots."
Solution: Negotiated SLA for 2 designated slots/week. C&W currently underutilizes evening/weekend capacity for self-pay.
"Consultants won't accept bundled fees."
Solution: Lead Consultant (Ollandini) has verified benchmarks. Integrated model increases patient volume, offsetting lower per-case fee.
Data Quality
All competitor pricing is validated from Jan 2026 published data. Cost assumptions for theatre and imaging are based on standard NHS Trust PPU internal transfer pricing models.
View Full Methodology Report